ClinicalTrials.gg
CompletedNCT03903341COLL-BSPUpdated Sep 16, 2022

The Role of the Upper Colliculus in the Idiopathic Blepharospasm

An interventional study of fMRI in Blepharospasm, Benign Essential, sponsored by University Hospital, Grenoble. Completed at 1 site in France. Open to participants aged 30 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-09-16.

Sponsored by University Hospital, Grenoble · Not applicable, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
13
Allocation
Non-randomized
Ages
30 Years to 70 Years
Sex
All
01

Study summary

This pilot study aims at investigating the role of superior colliculus in patients with idiopathic blepharospasm (BSP) de novo, compared to healthy subjects.

Read the detailed description

The objective of the study is to investigate the function of the superior colliculus (SC) related to visual stimulation by means of fMRI (functional magnetic resonance imaging) in patients with idiopathic BSP compared to healthy subjects. The hypothesis is that SC function is impaired in BSP (role of biomarker of SC).

02

Conditions studied

  • Blepharospasm, Benign Essential

Keywords

  • Superior colliculus
  • fMRI
03

In context

Lead sponsor

University Hospital, Grenoble is the lead sponsor of 838 studies on the registry; 208 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non treated idiopathic blepharospasm
  • Age: 30- 70 years

Exclusion criteria

Exclusion Criteria:

  • Under the following treatments: Botulin toxin, anticholinergic, benzodiazepines, baclofen, beta- and alpha-blockers collyrium
  • No MRI
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Other
    idiopathic blepharospasm (BSP) de novo

    bold signal in visual pathway

    Other: fMRI

  • Other
    Healthy subjects

    bold signal in visual pathway

    Other: fMRI

Interventions

  • OtherfMRI

    bold signal in visual pathway

06

What researchers measure

Primary outcomes

  1. Visual pathways fMRI

    To measure the bold signal in superior colliculus and lateral geniculate corpus

    Time frame: In a five months period after inclusion

07

Study locations

1 site
  • CHU Grenoble Alpes
    Grenoble, 38043, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2019 to primary completion in Nov 2021, 23 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2019
First posted
Apr 4, 2019
StartActual
Nov 20, 2019
Primary completionActual
Nov 19, 2021
CompletionActual
Nov 19, 2021
Last update
Sep 16, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03903341
Responsible party
Sponsor
First posted
Apr 4, 2019
Start date
Nov 20, 2019
Primary completion
Nov 19, 2021
Completion
Nov 19, 2021
Last update
Sep 16, 2022

Study contacts

Sara Meoni, MD, PhD
principal investigator · CHU Grenoble Alpes

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion